Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CV SciencesCVSI -0.20% EV-to-OCF is -10.19 as of Aug. 18, 2026. The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, CV Sciences ranks better than 88.76% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, CV Sciences's Enterprise Value is $5.02 Mil.
CV Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.49 Mil. Therefore, CV Sciences's EV-to-OCF for today is -10.19.
The historical rank and industry rank for CV Sciences's EV-to-OCF or its related term are showing as below:
CVSI'
s EV-to-OCF Range Over the Past 10 Years
Min: -102.31 Med: -4.91 Max: 2282.29
Current: -10.19
During the past 13 years, the highest EV-to-OCF of CV Sciences was 2282.29. The lowest was -102.31. And the median was -4.91.
CVSI's EV-to-OCF is ranked better than 88.76% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11
vs CVSI: -10.19
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CV Sciences's PE Ratio (TTM) for today is calculated as:
CV Sciences's share price for today is $0.01974.
CV Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CV Sciences EV-to-OCF Related Terms
CV Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for CV Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CV Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CV Sciences EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CV Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where CV Sciences's EV-to-OCF falls into.
CV Sciences's current Enterprise Value is $5.02 Mil.
CV Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CV Sciences (CVSI) has a EV-to-OCF of -10.19 as of Aug. 18, 2026. According to the industry distribution chart, CV Sciences ranks #113 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is CV Sciences' EV-to-OCF too high?
CV Sciences' current EV-to-OCF is -10.19. Based on the distribution chart, CV Sciences ranks #113 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CV Sciences' EV-to-OCF compare to AKAN and SNOA?
According to the Drug Manufacturers industry distribution chart, CV Sciences ranks #113 out of 1005 companies for EV-to-OCF. This places CV Sciences in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.00, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CV Sciences's current EV-to-OCF is -10.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CV Sciences stock overvalued right now?
Based on GuruFocus' analysis, CV Sciences (CVSI) is currently considered Possible Value Trap. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 34.2% below its estimated fair value. The current EV-to-OCF is -10.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For CV Sciences (CVSI), the current EV-to-OCF is -10.19 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CV Sciences Inc is a consumer wellness company specializing in nutraceuticals and plant-based foods products. It develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol. The company sells its products under tradenames, such as +PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox. The company's products are sold in a variety of market sectors, including nutraceutical, beauty care, and specialty foods. The company has one operating segment, which is the business of hemp-based CBD wellness products. Geographically, all of the company's revenue is generated from United States. The company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVSI has been successfully added to your 
